2018 Conference Program

Press Conference

Sunday, September 30, 2018  

8:30 am - 8:45 am

Welcome

8:45 am - 9:15 am

Keynote Address

9:15 am - 12:15 pm

Session 1: Regulating T Cells and Their Response to Cancer

Rafi Ahmed, Emory University

Christian Ottensmeier, University of Southampton

W. Nicholas Haining, Dana Farber Cancer Institute 

Nick Restifo, National Cancer Institute, NIH

12:15 pm - 2:45 pm

Lunch & Poster Session

The following topics will be presented:                            

2:45 pm - 6:15 pm

Session 2: Tackling the Tumor Microenvironment             

Shannon J. Turley, Genentech

David G. DeNardo, Washington University School of Medicine

Miriam Merad, Icahn School of Medicine at Mount Sinai

Leonid S. Metelitsa, Baylor College of Medicine

Dmitry Gabrilovich, The Wistar Institute


monday, october 1, 2018

8:15 am - 12:45 pm

Session 3: Genetically Engineered T Cells

James N. Kochendorfer, National Cancer Institute, NIH 

Crystal L. Mackall, Stanford University School of Medicine

Steven A. Rosenberg, National Cancer Institute, NIH

Christine E. Brown, City of Hope National Medical Center 

Michel Sadelain, Memorial Sloan Kettering Cancer Center

Philip D. Greenberg, Fred Hutchinson Cancer Research Center and University of Washington School of Medicine

12:45 pm - 2:15 pm

Lunch

2:15 pm - 5:45 pm

Session 4: Maintenance of Immune Balance: Effects of Targeted and Immune Therapies

Alberto Bardelli, University of Torino

David L. Porter, University of Pennsylvania

Sherene Loi, Peter MacCallum Cancer Centre

Patrick Hwu, The University of Texas M.D. Anderson Cancer Center

Antony Rosen, Johns Hopkins University School of Medicine


tuesDAY, october 2, 2018

8:00 am - 12:30 pm

Session 5: Novel Vaccine Platforms and Combinations

Robert D. Schreiber, Washington University School of Medicine

Ugur Sahin, BioNTech

Catherine J. Wu, Dana Farber Cancer Institute

Cornelis J.M. Melief, Leiden University Medical Center and ISA Pharmaceuticals

Alan Melcher, The Institute of Cancer Research

James J. Moon, University of Michigan

Robert Seder, National Institutes of Allergy and Infectious Diseases, NIH

12:30 pm - 3:00 pm

Lunch & Poster Session

The following topics will be presented:

3:00 pm - 6:30 pm

Session 6: Mutational Analysis and Predicting Response to Immunotherapy

Ton N. Schumacher, Netherlands Cancer Institute

Benjamin D. Greenbaum, Icahn School of Medicine at Mount Sinai

Naiyer Rizvi, Columbia University Medical Center

Drew M. Pardoll, Johns Hopkins University School of Medicine

Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center


wednesday, october 3, 2018

8:15 am - 10:45 am

Session 7: Convergence of Technology and Cancer Immunotherapy

Nir Hacohen, Broad Institute of MIT and Harvard

Dan Dongeun Huh, University of Pennsylvania

Darrell Irvine, MIT

10:45 am - 12:45 pm

Session 8: Microbiome and Metabolism

Hassane M. Zarour, University of Pittsburgh

Jennifer A. Wargo, The University of Texas M.D. Anderson Cancer Center

Yasmine Belkaid, National Institutes of Health


The Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Mainz, Germany, 06/09/2017-09/09/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 22 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.